Your browser is no longer supported. Please, upgrade your browser.
ICPT [NASD]
Intercept Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-3.25 Insider Own3.70% Shs Outstand31.74M Perf Week-4.64%
Market Cap492.74M Forward P/E- EPS next Y-3.60 Insider Trans0.00% Shs Float24.38M Perf Month-5.52%
Income-107.30M PEG- EPS next Q-0.54 Inst Own77.90% Short Float34.34% Perf Quarter13.39%
Sales354.30M P/S1.39 EPS this Y23.40% Inst Trans0.40% Short Ratio10.39 Perf Half Y-4.25%
Book/sh-4.92 P/B- EPS next Y-21.00% ROA-20.00% Target Price29.71 Perf Year-55.92%
Cash/sh14.01 P/C1.17 EPS next 5Y-8.89% ROE59.10% 52W Range11.60 - 38.94 Perf YTD-33.48%
Dividend- P/FCF- EPS past 5Y2.70% ROI-58.70% 52W High-58.01% Beta1.45
Dividend %- Quick Ratio3.50 Sales past 5Y157.10% Gross Margin99.20% 52W Low40.95% ATR1.01
Employees498 Current Ratio3.50 Sales Q/Q16.70% Oper. Margin-16.60% RSI (14)40.43 Volatility6.11% 6.05%
OptionableYes Debt/Eq- EPS Q/Q94.30% Profit Margin-30.30% Rel Volume0.90 Prev Close16.43
ShortableYes LT Debt/Eq- EarningsNov 03 BMO Payout- Avg Volume805.86K Price16.35
Recom2.70 SMA20-9.63% SMA50-3.24% SMA200-12.60% Volume355,333 Change-0.49%
Aug-20-21Downgrade Goldman Neutral → Sell $17 → $10
May-25-21Downgrade B. Riley Securities Buy → Neutral $18
Mar-12-21Upgrade H.C. Wainwright Sell → Neutral $21
Feb-23-21Downgrade H.C. Wainwright Neutral → Sell $25
Jan-15-21Downgrade BofA Securities Neutral → Underperform $40 → $27
Dec-21-20Downgrade Jefferies Buy → Hold $30
Nov-10-20Upgrade Robert W. Baird Neutral → Outperform $52
Nov-10-20Upgrade Raymond James Mkt Perform → Outperform $60
Jul-31-20Initiated Piper Sandler Overweight $82
Jul-21-20Downgrade JMP Securities Mkt Outperform → Mkt Perform
Jun-30-20Upgrade Citigroup Neutral → Buy
Jun-30-20Downgrade UBS Buy → Neutral $135 → $57
Jun-30-20Downgrade Robert W. Baird Outperform → Neutral $52
Jun-30-20Downgrade Credit Suisse Outperform → Neutral $137 → $59
Jun-30-20Downgrade Cowen Outperform → Market Perform $47
Jun-30-20Downgrade Cantor Fitzgerald Overweight → Neutral
Jun-29-20Downgrade Wells Fargo Overweight → Equal Weight
Jun-29-20Downgrade RBC Capital Mkts Outperform → Sector Perform $117 → $55
Jun-29-20Downgrade Oppenheimer Outperform → Perform
Jun-29-20Downgrade Goldman Buy → Neutral $150 → $60
Nov-15-21 10:16AM  
08:00AM  
Nov-11-21 08:00AM  
Nov-04-21 06:08AM  
Nov-03-21 03:31PM  
08:15AM  
07:00AM  
05:51AM  
Nov-02-21 08:00AM  
Oct-27-21 08:00AM  
Oct-23-21 08:00AM  
Oct-14-21 10:11AM  
Sep-29-21 08:47AM  
Sep-25-21 10:06AM  
Sep-21-21 08:00AM  
Sep-13-21 08:00AM  
Sep-08-21 06:06AM  
Sep-01-21 08:00AM  
Aug-20-21 10:30AM  
Aug-10-21 09:43PM  
06:06AM  
Jul-31-21 06:00AM  
Jul-30-21 09:00PM  
01:18PM  
Jul-29-21 08:15AM  
07:00AM  
Jul-22-21 03:03PM  
Jul-19-21 11:00AM  
07:00AM  
Jun-21-21 08:00AM  
Jun-15-21 08:00AM  
Jun-13-21 06:36AM  
Jun-09-21 08:00AM  
Jun-07-21 08:00AM  
May-27-21 12:38PM  
11:43AM  
08:00AM  
May-26-21 04:30PM  
02:24PM  
May-12-21 08:00AM  
May-10-21 04:58AM  
May-07-21 12:23PM  
12:30AM  
May-06-21 08:35AM  
07:00AM  
06:45AM  
Apr-30-21 06:06AM  
Apr-29-21 05:06PM  
Apr-26-21 08:00AM  
Apr-23-21 10:02AM  
Apr-21-21 05:51AM  
Apr-04-21 06:06AM  
Mar-27-21 11:31AM  
Mar-24-21 09:47PM  
Mar-15-21 06:06AM  
Mar-10-21 08:00AM  
Feb-26-21 12:19PM  
Feb-25-21 12:00PM  
07:00AM  
06:30AM  
Feb-19-21 08:00AM  
Feb-17-21 08:00AM  
08:00AM  
Feb-11-21 08:00AM  
Feb-01-21 10:05PM  
Jan-27-21 01:35PM  
Jan-23-21 06:35AM  
Jan-11-21 08:00AM  
Jan-05-21 08:00AM  
Jan-04-21 12:45PM  
11:53AM  
11:45AM  
11:12AM  
09:47AM  
09:31AM  
09:15AM  
08:30AM  
06:20AM  
Jan-03-21 11:45PM  
12:10PM  
11:00AM  
10:30AM  
Jan-02-21 11:19PM  
04:00PM  
Jan-01-21 09:00PM  
07:15PM  
Dec-31-20 03:00PM  
02:12PM  
01:40PM  
12:42PM  
12:40PM  
11:45AM  
11:40AM  
Dec-30-20 02:40PM  
01:55PM  
10:30AM  
10:00AM  
10:00AM  
Dec-29-20 02:30PM  
01:15PM  
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. Its lead products candidate is the Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid in adults. The company is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis (NASH); and other product candidates in various stages of clinical and preclinical development. It has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. The company markets its products through an internal commercial organization, a contract sales organization, and third-party distributors. Intercept Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
AKKARAJU SRINIVASDirectorMar 12Buy21.29147,0003,129,630640,688Mar 12 07:51 PM
AKKARAJU SRINIVASDirectorMar 10Buy20.9690,0001,886,622493,688Mar 12 07:51 PM
Kapadia SandipCFO and TreasurerJan 05Sale24.472,19353,66323,764Jan 05 07:01 PM
Kapadia SandipCFO and TreasurerDec 15Sale32.781,76357,79127,158Dec 16 07:00 PM